SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are surging due to positive Phase 3 trial results for its personalized mRNA cancer vaccine, triggering a massive short squeeze that has drawn heavy retail interest and intense debate over the company's valuation. While bulls are celebrating a breakthrough in oncology and the potential for a transformative treatment platform, skeptics are cautioning that the rally is an overreaction driven by speculative momentum rather than immediate commercial viability.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a major rally fueled by a massive short squeeze, significant ETF inflows, and market anticipation surrounding a high-profile White House meeting on digital asset policy. The community is actively discussing the potential end of the crypto winter, with bullish sentiment surging as bears face widespread liquidations and traders monitor FOMC minutes for further market volatility.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is facing heightened market activity as traders react to shifting macroeconomic data and community speculation surrounding potential regulatory developments. While sentiment remains divided, many market participants are closely monitoring price support levels and institutional inflows as catalysts for the next phase of the cycle.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors react to the company's updated revenue outlook and ongoing progress in its Sanofi licensing partnership, specifically regarding Phase 3 development for their combination vaccine. While management highlights positive engagement and active oncology collaborations through its Matrix-M platform, community sentiment remains split between optimism for future licensing deals and frustration over the slow pace of catalyst delivery.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BitMine Immersion Technologies is currently experiencing high volatility as investors closely monitor pending legislative developments regarding the Clarity Act and the broader performance of Ethereum. Community sentiment is deeply polarized, with bullish traders highlighting significant share buybacks and treasury growth as catalysts for a potential squeeze, while skeptics express frustration over past dilution and management's strategic communication.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors rally behind positive clinical updates and the company's progress toward a BLA submission for its prostate cancer therapy, fueling widespread speculation about a potential multi-billion dollar buyout by Big Pharma. The community is actively discussing the stock's significant institutional accumulation, robust biomarker data, and the potential for a massive valuation re-rate as the firm approaches key late-stage development milestones.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as speculative momentum builds around a potential takeover bid by Nelson Peltz, with the community actively monitoring heavy short interest and institutional accumulation as catalysts for a possible short squeeze. Investors are debating the timing of a formal buyout announcement while encouraging others to lock up shares to restrict supply and apply upward pressure on the stock.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is rallying significantly as investors pivot into the company following positive clinical trial results for a Moderna-Merck cancer vaccine, which highlights the strategic value of Tempus's data and genomic platform in the burgeoning precision oncology market. Community sentiment is increasingly bullish, with traders actively discussing the potential for a short squeeze given the high short interest and pointing toward strong institutional support as long-term validation for the stock's growth trajectory.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a significant revenue beat in the most recent quarter, combined with positive developments regarding its flagship product YARTEMLEA and the strategic repayment of debt. The community is actively discussing the company's improved fundamental outlook, the potential for a short squeeze, and the anticipated impact of forthcoming regulatory and reimbursement milestones.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck & Co. is trending due to the positive Phase 3 results for its personalized mRNA melanoma vaccine, intismeran, which was developed in partnership with Moderna. The community is actively debating the commercial potential of this new oncology platform, with many investors highlighting Merck's strategic need to diversify its pipeline ahead of the Keytruda patent cliff.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Addus HomeCare (ADUS) Just Flashed Golden Cross Signal: Do You Buy?

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

Addus HomeCare Announces Departure of Heather Dixon and Return of Brad Bickham as Chief Operating Officer on an Interim Basis

Addus HomeCare Corporation (Nasdaq: ADUS) (the Company), a provider of home care services, announced today that Heather Dixon, President and Chief Operating Officer, is no longer with the Company. Brad Bickham, former President and Chief Operating Officer at Addus, has agreed to return as Chief...

ADUS vs. ELAN: Which Stock Is the Better Value Option?

Are Medical Stocks Lagging  Novavax (NVAX) This Year?

Here is how Novavax (NVAX) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

Addus HomeCare (ADUS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Addus HomeCare (ADUS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Addus HomeCare (ADUS) Surpasses Q2 Earnings and Revenue Estimates

Addus HomeCare (ADUS) delivered earnings and revenue surprises of +2.37% and +0.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare Announces Second Quarter 2026 Financial Results

Addus HomeCare Corporation (NASDAQ: ADUS), a provider of home care services, today announced its financial results for the second quarter and six months ended June 30, 2026. Second Quarter 2026 Highlights: Net Service Revenues Increase 8.0% to $377.4 Million Net Income of $27.6 Million, or $1.49...

Can Volume Growth and RPT Recovery Support DaVita's Q2 Earnings?

DVA's Q2 results are likely to benefit from volume growth and RPT recovery, but payor mix pressure and spending on technology could limit margin gains.

Quest Diagnostics (DGX) Surpasses Q2 Earnings and Revenue Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of +11.03% and +2.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare Announces Second Quarter 2026 Earnings Release and Conference Call

Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, announced today that it will release earnings for the second quarter ended June 30, 2026, on Monday, August 3, 2026, after the market close. Addus HomeCare will host a conference call on Tuesday, August 4, 2026, at 9:00...

Addus HomeCare Corp. engages in the provision of in-home personal care services. It operates through the following segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill or disabled. The Hospice segment includes physical, emotional, and spiritual care for people who are terminally ill as well as related services for its families. The Home Health segment offers services that are primarily medical in nature to individuals who may require assistance during an illness or after hospitalization and include skilled nursing and physical, occupational, and speech therapy. The company was founded 1979 and is headquartered in Frisco, TX.

Addus HomeCare Corporation

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ADUSAddus HomeCare Corporation

Fundamentals

Connect Stocktwits to ChatGPT

Latest ADUS News